Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Sunscreening Agents
Interventions: BAY987517, BullFrog Gel Sunscreen Land Sport SPF-50; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Obesity
Interventions: Teaching Kitchen Collaborative Curriculum; Behavioral
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 25 Years to 70 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Irvine, California • Los Angeles, California • Boston, Massachusetts + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GEM + CGM; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 35 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Psoriatic Arthritis
Interventions: Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more

Conditions: Von Willebrand Disease
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: CP-945,598 Treatment B, CP-945,598 Treatment A, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Peoria, Arizona • Newport Beach, California • Miami, Florida + 12 more

Conditions: COPD
Interventions: LAIV; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Alzheimer Disease, At Risk, Alzheimer Disease, Protection Against, Dementia
Interventions: Gamification; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 55 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Carbon Monoxide Poisoning
Interventions: Hyperbaric Oxygen (HBO2) - 3 sessions, Hyperbaric Oxygen (HBO2) - 1 session; Combination Product
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 79 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Osteoarthritis
Interventions: Povidone iodine, Vancomycin powder, Conventional; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Rancho Mirage, California • Denver, Colorado • Weston, Florida + 6 more

Conditions: Diabetes Mellitus, Type 2
Interventions: CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miramar, Florida • San Antonio, Texas • Tacoma, Washington

Conditions: Severe Obesity, Obesity, BMI Greater Than 30
Interventions: Tirzepatide, Standard of Care post-gastric bypass; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 25 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sickle Cell Disease, Vaso-occlusive Pain Episodes
Interventions: KindVR Aqua Program; Device
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 8 Years to 21 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions: Insulin, Placebo (Sterile diluent); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: Physical Activity; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 21 Years to 60 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 2
States / cities: Greenville, North Carolina • Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: HIV Test Offer, General Health Screen Offer; Behavioral
Lead sponsor: North Bronx Healthcare Network; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Parkinson Disease
Interventions: Standard of care + Mediterranean diet (intervention), Standard of care (control); Other
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 85 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Interventions: Catheter ablation, Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation, Insertion of CardioMems Hemodynamic monitor, Empiric heart failure drug therapy; Device · Drug
Lead sponsor: Electrophysiology Research Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Flagstaff, Arizona • Jonesboro, Arkansas • Littleton, Colorado + 4 more

Conditions: Pruritus, Atopic Dermatitis
Interventions: difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 61
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more

Conditions: Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders, Myelodysplastic Syndromes, Platelet Refractoriness
Interventions: Thrombosomes, Liquid Stored Platelets (LSP); Biological
Lead sponsor: Cellphire Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Duarte, California • Washington D.C., District of Columbia • Nashville, Tennessee + 1 more

Conditions: Prediabetic State
Interventions: Heat therapy, High-intensity interval training; Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 50 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Parkinson Disease, Fatigue, Parkinsonism
Interventions: Northera, Placebo Oral Tablet; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Acne Vulgaris
Interventions: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient); Combination Product
Lead sponsor: Biofrontera Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more

Conditions: Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions: Lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 14,673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 373
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more

Search by objective public record fields.

Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)

Teaching Kitchen Multisite Trial

The Use of Libre to Improve Metabolic Control and Reduce Reliance on Medication

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Collection of Blood in Normal Subjects and Subjects With Von Willebrand Disease (VWD)

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)

The STEP 4Life Trial

One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning

Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Virtual Reality As Adjunct Therapy for Vaso-Occlusive Pain

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

Physical Activity Following Surgery Induced Weight Loss

The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies

Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease a Randomized, Controlled, Clinical Trial

Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

Thrombosomes® in Bleeding Thrombocytopenic Patients Study

Heat and Exercise in Aging as Therapy (HEAT)

A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors